Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor

Evangelos Terpos, Athina Mougiou, Niki Stavroyianni, Alexandra Kouraklis, Nikolaos Giannakoulas, Nicholas C. Zoumbos, Aria Hatzivassili, Olga Liapi, Maria Vassilaki, Konstantinos L. Bourantas, Evridiki Michalis, Nikolaos I. Anagnostopoulos, Nikolaos P. Laoutaris, Eleni Manioudaki, Maria Protopappa, Vassiliki Bakaloudi, John I. Christakis, Elissavet Grouzi, Nora Athina Viniou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previous studies have shown that treatment with erythropoietin (Epo) improves anemia in approximately 20% of patients (pts) with myelodysplastic syndromes (MDS) whereas combination treatment with granulocyte colony-stimulating factor (G-CSF) may increase the response rate (RR). The aim of the present Greek multicenter study was to evaluate the RR and the response duration of the prolonged administration of Epo or Epo plus G-CSF in MDS pts. The eligibility criteria for entrance in the study were: primary MDS, Hb levels < 9g/dl and no clinically significant organ disease. 249 pts (169M/80F) with a median age of 74.5 years were included in this study: 94 RA, 61 RARS, 56 RAEB, 12 RAEB-t and 26 CMML. 194 pts were treated with Epo alone (Epo group) and 55 were treated with the combination of Epo plus G-CSF (combination group-CG). Epo was given on alternate days at a dose of 150U/kg, sc, for at least 6 months. G-CSF was administered daily, sc, at a dose of Sjig/kg. The erythroid response was defined as complete (CR) if an increase of Hb values above 2g/dl or a 100% decrease in transfusion requirements for at least 6 weeks were observed. An increase of Hb values of l-2g/dl and even a minimum decrease in transfusion requirements were considered as partial response (PR). In the Epo group the RR was 38.3% (28.5% CR and 9.8% PR) whereas in the CG it was 32.7% (27.2% CR and 5.5% PR). In the Epo group the RR for RA and RARS pts was 37.5% and 47.3% respectively while in the CG it was 31.8% and 26.3% respectively. In the Epo group response duration had a median time of 11 months and in the CG of 14 months. Kaplan-Meier analysis showed no differences between the two groups with respect to the time the response occurred. The median time for response was 6 months for both groups. The probability of response increases significantly with treatment duration in both groups. Time to treatment failure did not differ between the two groups. Multivariate analysis showed that MDS subtype was the most significant prognostic factor for response to treatment. These results suggest that prolonged administration of Epo or Epo and G-CSF might increase the RR in pts with MDS.

Original languageEnglish (US)
JournalBlood
Volume96
Issue number11 PART I
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Granulocyte Colony-Stimulating Factor
Erythropoietin
Anemia
Therapeutics
Refractory Anemia with Excess of Blasts
Kaplan-Meier Estimate
Treatment Failure
Multicenter Studies
Multivariate Analysis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Terpos, E., Mougiou, A., Stavroyianni, N., Kouraklis, A., Giannakoulas, N., Zoumbos, N. C., ... Viniou, N. A. (2000). Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor. Blood, 96(11 PART I).

Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor. / Terpos, Evangelos; Mougiou, Athina; Stavroyianni, Niki; Kouraklis, Alexandra; Giannakoulas, Nikolaos; Zoumbos, Nicholas C.; Hatzivassili, Aria; Liapi, Olga; Vassilaki, Maria; Bourantas, Konstantinos L.; Michalis, Evridiki; Anagnostopoulos, Nikolaos I.; Laoutaris, Nikolaos P.; Manioudaki, Eleni; Protopappa, Maria; Bakaloudi, Vassiliki; Christakis, John I.; Grouzi, Elissavet; Viniou, Nora Athina.

In: Blood, Vol. 96, No. 11 PART I, 01.12.2000.

Research output: Contribution to journalArticle

Terpos, E, Mougiou, A, Stavroyianni, N, Kouraklis, A, Giannakoulas, N, Zoumbos, NC, Hatzivassili, A, Liapi, O, Vassilaki, M, Bourantas, KL, Michalis, E, Anagnostopoulos, NI, Laoutaris, NP, Manioudaki, E, Protopappa, M, Bakaloudi, V, Christakis, JI, Grouzi, E & Viniou, NA 2000, 'Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor', Blood, vol. 96, no. 11 PART I.
Terpos E, Mougiou A, Stavroyianni N, Kouraklis A, Giannakoulas N, Zoumbos NC et al. Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor. Blood. 2000 Dec 1;96(11 PART I).
Terpos, Evangelos ; Mougiou, Athina ; Stavroyianni, Niki ; Kouraklis, Alexandra ; Giannakoulas, Nikolaos ; Zoumbos, Nicholas C. ; Hatzivassili, Aria ; Liapi, Olga ; Vassilaki, Maria ; Bourantas, Konstantinos L. ; Michalis, Evridiki ; Anagnostopoulos, Nikolaos I. ; Laoutaris, Nikolaos P. ; Manioudaki, Eleni ; Protopappa, Maria ; Bakaloudi, Vassiliki ; Christakis, John I. ; Grouzi, Elissavet ; Viniou, Nora Athina. / Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor. In: Blood. 2000 ; Vol. 96, No. 11 PART I.
@article{82a17f680e6e4848a19dc95948702cf3,
title = "Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor",
abstract = "Previous studies have shown that treatment with erythropoietin (Epo) improves anemia in approximately 20{\%} of patients (pts) with myelodysplastic syndromes (MDS) whereas combination treatment with granulocyte colony-stimulating factor (G-CSF) may increase the response rate (RR). The aim of the present Greek multicenter study was to evaluate the RR and the response duration of the prolonged administration of Epo or Epo plus G-CSF in MDS pts. The eligibility criteria for entrance in the study were: primary MDS, Hb levels < 9g/dl and no clinically significant organ disease. 249 pts (169M/80F) with a median age of 74.5 years were included in this study: 94 RA, 61 RARS, 56 RAEB, 12 RAEB-t and 26 CMML. 194 pts were treated with Epo alone (Epo group) and 55 were treated with the combination of Epo plus G-CSF (combination group-CG). Epo was given on alternate days at a dose of 150U/kg, sc, for at least 6 months. G-CSF was administered daily, sc, at a dose of Sjig/kg. The erythroid response was defined as complete (CR) if an increase of Hb values above 2g/dl or a 100{\%} decrease in transfusion requirements for at least 6 weeks were observed. An increase of Hb values of l-2g/dl and even a minimum decrease in transfusion requirements were considered as partial response (PR). In the Epo group the RR was 38.3{\%} (28.5{\%} CR and 9.8{\%} PR) whereas in the CG it was 32.7{\%} (27.2{\%} CR and 5.5{\%} PR). In the Epo group the RR for RA and RARS pts was 37.5{\%} and 47.3{\%} respectively while in the CG it was 31.8{\%} and 26.3{\%} respectively. In the Epo group response duration had a median time of 11 months and in the CG of 14 months. Kaplan-Meier analysis showed no differences between the two groups with respect to the time the response occurred. The median time for response was 6 months for both groups. The probability of response increases significantly with treatment duration in both groups. Time to treatment failure did not differ between the two groups. Multivariate analysis showed that MDS subtype was the most significant prognostic factor for response to treatment. These results suggest that prolonged administration of Epo or Epo and G-CSF might increase the RR in pts with MDS.",
author = "Evangelos Terpos and Athina Mougiou and Niki Stavroyianni and Alexandra Kouraklis and Nikolaos Giannakoulas and Zoumbos, {Nicholas C.} and Aria Hatzivassili and Olga Liapi and Maria Vassilaki and Bourantas, {Konstantinos L.} and Evridiki Michalis and Anagnostopoulos, {Nikolaos I.} and Laoutaris, {Nikolaos P.} and Eleni Manioudaki and Maria Protopappa and Vassiliki Bakaloudi and Christakis, {John I.} and Elissavet Grouzi and Viniou, {Nora Athina}",
year = "2000",
month = "12",
day = "1",
language = "English (US)",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART I",

}

TY - JOUR

T1 - Treatment of anemia in myelodysplastic syndromes with prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor

AU - Terpos, Evangelos

AU - Mougiou, Athina

AU - Stavroyianni, Niki

AU - Kouraklis, Alexandra

AU - Giannakoulas, Nikolaos

AU - Zoumbos, Nicholas C.

AU - Hatzivassili, Aria

AU - Liapi, Olga

AU - Vassilaki, Maria

AU - Bourantas, Konstantinos L.

AU - Michalis, Evridiki

AU - Anagnostopoulos, Nikolaos I.

AU - Laoutaris, Nikolaos P.

AU - Manioudaki, Eleni

AU - Protopappa, Maria

AU - Bakaloudi, Vassiliki

AU - Christakis, John I.

AU - Grouzi, Elissavet

AU - Viniou, Nora Athina

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Previous studies have shown that treatment with erythropoietin (Epo) improves anemia in approximately 20% of patients (pts) with myelodysplastic syndromes (MDS) whereas combination treatment with granulocyte colony-stimulating factor (G-CSF) may increase the response rate (RR). The aim of the present Greek multicenter study was to evaluate the RR and the response duration of the prolonged administration of Epo or Epo plus G-CSF in MDS pts. The eligibility criteria for entrance in the study were: primary MDS, Hb levels < 9g/dl and no clinically significant organ disease. 249 pts (169M/80F) with a median age of 74.5 years were included in this study: 94 RA, 61 RARS, 56 RAEB, 12 RAEB-t and 26 CMML. 194 pts were treated with Epo alone (Epo group) and 55 were treated with the combination of Epo plus G-CSF (combination group-CG). Epo was given on alternate days at a dose of 150U/kg, sc, for at least 6 months. G-CSF was administered daily, sc, at a dose of Sjig/kg. The erythroid response was defined as complete (CR) if an increase of Hb values above 2g/dl or a 100% decrease in transfusion requirements for at least 6 weeks were observed. An increase of Hb values of l-2g/dl and even a minimum decrease in transfusion requirements were considered as partial response (PR). In the Epo group the RR was 38.3% (28.5% CR and 9.8% PR) whereas in the CG it was 32.7% (27.2% CR and 5.5% PR). In the Epo group the RR for RA and RARS pts was 37.5% and 47.3% respectively while in the CG it was 31.8% and 26.3% respectively. In the Epo group response duration had a median time of 11 months and in the CG of 14 months. Kaplan-Meier analysis showed no differences between the two groups with respect to the time the response occurred. The median time for response was 6 months for both groups. The probability of response increases significantly with treatment duration in both groups. Time to treatment failure did not differ between the two groups. Multivariate analysis showed that MDS subtype was the most significant prognostic factor for response to treatment. These results suggest that prolonged administration of Epo or Epo and G-CSF might increase the RR in pts with MDS.

AB - Previous studies have shown that treatment with erythropoietin (Epo) improves anemia in approximately 20% of patients (pts) with myelodysplastic syndromes (MDS) whereas combination treatment with granulocyte colony-stimulating factor (G-CSF) may increase the response rate (RR). The aim of the present Greek multicenter study was to evaluate the RR and the response duration of the prolonged administration of Epo or Epo plus G-CSF in MDS pts. The eligibility criteria for entrance in the study were: primary MDS, Hb levels < 9g/dl and no clinically significant organ disease. 249 pts (169M/80F) with a median age of 74.5 years were included in this study: 94 RA, 61 RARS, 56 RAEB, 12 RAEB-t and 26 CMML. 194 pts were treated with Epo alone (Epo group) and 55 were treated with the combination of Epo plus G-CSF (combination group-CG). Epo was given on alternate days at a dose of 150U/kg, sc, for at least 6 months. G-CSF was administered daily, sc, at a dose of Sjig/kg. The erythroid response was defined as complete (CR) if an increase of Hb values above 2g/dl or a 100% decrease in transfusion requirements for at least 6 weeks were observed. An increase of Hb values of l-2g/dl and even a minimum decrease in transfusion requirements were considered as partial response (PR). In the Epo group the RR was 38.3% (28.5% CR and 9.8% PR) whereas in the CG it was 32.7% (27.2% CR and 5.5% PR). In the Epo group the RR for RA and RARS pts was 37.5% and 47.3% respectively while in the CG it was 31.8% and 26.3% respectively. In the Epo group response duration had a median time of 11 months and in the CG of 14 months. Kaplan-Meier analysis showed no differences between the two groups with respect to the time the response occurred. The median time for response was 6 months for both groups. The probability of response increases significantly with treatment duration in both groups. Time to treatment failure did not differ between the two groups. Multivariate analysis showed that MDS subtype was the most significant prognostic factor for response to treatment. These results suggest that prolonged administration of Epo or Epo and G-CSF might increase the RR in pts with MDS.

UR - http://www.scopus.com/inward/record.url?scp=33748642773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748642773&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748642773

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -